Cache Advisors LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cache Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 3,860 shares of the biopharmaceutical company's stock, valued at approximately $2,750,000. Regeneron Pharmaceuticals accounts for approximately 1.0% of Cache Advisors LLC's portfolio, making the stock its 22nd largest holding.

Other institutional investors also recently modified their holdings of the company. Pamalican Asset Management Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $4,915,000. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $356,000. Rhenman & Partners Asset Management AB lifted its position in shares of Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after acquiring an additional 4,457 shares during the period. Fagan Associates Inc. lifted its position in shares of Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after acquiring an additional 3,832 shares during the period. Finally, Golden State Equity Partners raised its holdings in Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after buying an additional 1,272 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. The Goldman Sachs Group lowered their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Bank of America lowered their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective on the stock. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, Citigroup upgraded shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $600.00 to $700.00 in a report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $890.60.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded up $14.92 on Tuesday, reaching $603.26. 876,067 shares of the company's stock were exchanged, compared to its average volume of 801,676. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market cap of $65.13 billion, a price-to-earnings ratio of 15.76, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20. The stock has a fifty day simple moving average of $590.70 and a 200-day simple moving average of $672.23.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 EPS. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.